Saturday, October 31, 2026

Deutsche Bank Already 4% Down, Almost Four Hours Before The Market Open

Deutsche Bank Already 4% Down, Almost Four Hours Before The Market Open

(VIANEWS) - The NYSE opens in less than four hours and Deutsche Bank's pre-market value is already 4.97% down.

Deutsche Bank's last close was $11.26, 17.02% under its 52-week high of $13.57.

The last session, NYSE ended with Deutsche Bank (DB) rising 3.59% to $11.26. NYSE rose 1.22% to $14,944.74, following the last session's upward trend on what was an all-around bullish trend trading session.

About Deutsche Bank

Deutsche Bank Aktiengesellschaft provides investment, financial, and related products and services to private individuals, corporate entities, and institutional clients worldwide. Its Corporate Bank segment provides cash management, trade finance and lending, trust and agency, foreign exchange, and securities services, as well as risk management solutions. The company's Investment Bank segment offers merger and acquisitions, and equity advisory services. This segment also focuses on financing, advisory, fixed income, risk management, sales and trading, and currency activities. The company's Private Bank segment provides payment and account services, and credit and deposit products, as well as investment advice products, such as environmental, social, and governance products. This segment also provides wealth management services, postal and parcel services, and digital offerings. The company's Asset Management segment provides investment solutions, such as alternative investments, which include real estate, infrastructure, private equity, liquid real assets, and sustainable investments; passive investments; and various other services, including insurance and pension solutions, asset liability management, portfolio management solutions, asset allocation advisory, structuring, and overlay to institutions, governments, corporations and foundations, and individual investors. As of December 31, 2021, it operated through 1,709 branches in 58 countries. The company was founded in 1870 and is headquartered in Frankfurt am Main, Germany.

Earnings Per Share

As for profitability, Deutsche Bank has a trailing twelve months EPS of $0.76.

PE Ratio

Deutsche Bank has a trailing twelve months price to earnings ratio of 14.85. Meaning, the purchaser of the share is investing $14.85 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.86%.

Growth Estimates Quarters

The company's growth estimates for the ongoing quarter and the next is 13.2% and 30.6%, respectively.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on May 17, 2023, the estimated forward annual dividend rate is 0.33 and the estimated forward annual dividend yield is 2.62%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 1.1%, now sitting on 25.68B for the twelve trailing months.

More news about Deutsche Bank (DB).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com